ICAAC Briefs: BioCryst Flu Candidate Rapivab, Melinta’s Delafloxacin For Gonorrhea And More
Executive Summary
The Interscience Conference on Antimicrobial Agents and Chemotherapy included presentations on Phase I study of delafloxacin for uncomplicated gonorrhea, Biocryst’s placebo-controlled flu trials of Rapivab and in vitro studies of Theravance’s Vibativ versus vancomycin.